Oversulfated chondroitin sulfate interaction with heparin-binding proteins: New insights into adverse reactions from contaminated heparins

Biochemical Pharmacology

Volumn 78, Issue 3, 2009, Pages 292-300

  Li, Boyangzi ^a   Suwan, Jiraporn ^b,c   Martin, Jeffrey G ^a,b   Zhang, Fuming ^d   Zhang, Zhenqing ^a   Hoppensteadt, Debra ^e   Clark, Melanie ^e   Fareed, Jawed ^e   Linhardt, Robert J ^a,b,d  

^a Research Rensselaer Polytechnic Institute   (United States)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^c THAMMASAT UNIVERSITY   (Thailand)

^d RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Antithrombin III; Factor XIIa; Heparin; Oversulfated chondroitin sulfate; Surface plasmon resonance

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 12A; BRADYKININ; CHONDROITIN SULFATE; HEPARIN; HEPARIN BINDING PROTEIN; HEPARIN COFACTOR II; KALLIKREIN; KININ; THROMBIN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; DRUG BINDING; DRUG CONTAMINATION; DRUG SAFETY; KALLIKREIN KININ SYSTEM; PRIORITY JOURNAL; PROTEIN CONFORMATION; SULFATION; SURFACE PLASMON RESONANCE;

ANTICOAGULANTS; ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD PROTEINS; CARBOHYDRATE SEQUENCE; CARRIER PROTEINS; CHONDROITIN SULFATES; DRUG CONTAMINATION; HEPARIN; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; SURFACE PLASMON RESONANCE;

EID: 65749088905     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.04.012     Document Type: Article

References (28)

1. Capila I., and Linhardt R.J. Heparin-protein interactions. Angew Chem Int Ed Engl 41 (2002) 391-412
2. Linhardt R.J. Heparin: structure and activity. J Med Chem 46 (2003) 2551-2554
3. Linhardt R.J., and Toida T. Heparin oligosaccharides: new analogues-development and applications. In: Witczak Z.B., and Nieforth K.A. (Eds). Carbohydrates in drug design (1997), Marcel Dekker, New York 277-341
4. Brister SJ, Buchanan MR, Griffin CC, Van Gorp CL, Linhardt RJ. Dermatan disulfate, an inhibitor of thrombin and complement activation. U.S. Patent 5,922,690; 1999.
5. Linhardt R.J. Heparin: an important drug enters its seventh decade. Chem Ind 2 (1991) 45-50
6. Linhardt R.J., and Gunay N.S. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 25 (1999) 5-16
7. Volpi N. Chondroitin sulfate: structure, role and pharmacological activity (2006), Elsevier, London
8. Maruyama T., Toida T., Imanari T., Yu G., and Linhardt R.J. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr Res 306 (1998) 35-43
9. Kishimoto T.K., Viswanathan K., Ganguly T., Elankumaran S., Smith S., Pelzer K., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 358 (2008) 2457-2467
10. Guerrini M., Beccati D., Shriver Z., Naggi A., Viswanathan K., Bahse L., et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 26 (2008) 669-675
11. Law R.H., Zhang Q., McGown S., Buckle A.M., Silverman G.A., Wong W., et al. An overview of the serpin superfamily. Genome Biol 7 (2006) 216
12. Carranza Y.E., Durand-Rougley C., and Doctor V. Effect of oversulfation on the chemical and biological properties of chondroitin-4-sulfate. Blood Coag Fibrin 19 (2008) 483-487
13. Moreau M.E., Garbacki N., Molinaro G., Brown N.J., Marceau F., and Adam A. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 99 (2005) 6-38
14. Hamad O.A., Ekdahl K.N., Nilsson P.H., Andersson J., Magotti P., Lambri J.D., et al. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost 6 (2008) 1413-1421
15. Edens R.E., Linhardt R.J., and Weiler J.M. Heparin is not just an anticoagulant anymore: six and one-half decades of studies on the ability of heparin to regulate complement activation. Complement Profiles 1 (1993) 96-120
16. Yu H., Muñoz E.M., Zhang F., Edens R.E., and Linhardt R.J. Kinetic studies on the interaction of heparin and complement proteins using surface plasmon resonance. Biochem Biophys Acta 1726 (2005) 168-176
17. Nadkarni V.D., Toida T., Van Gorp C.L., Schubert R.L., Weiler J.M., Hansen K.P., et al. Preparation and biological activity of N-sulfonated chondroitin and dermatan sulfate derivatives. Carbohydr Res 290 (1996) 87-96
18. Gozzo A.J., Nues V.A., Carmona A.K., Nader H.B., von Dietrich C., Silveira V.L., et al. Glycosaminoglycans affect the action of human plasma kallikrein on kininogen hydrolysis and inflammation. Immunopharmacology 2 (2002) 1861-1865
19. Renne T., Schuh K., and Muller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J Immunol 175 (2005) 3377-3385
20. Zhang Z., Weïwer M., Li B., Kemp M.M., Daman T.H., and Linhardt R.J. Oversulfated chondroitin sulfate: impact of a heparin impurity associated with adverse clinical events on low molecular weight heparin preparation. J Med Chem 51 (2008) 5498-5501
21. Sanchez J., Elgue G., Riesenfeld J., and Olsson P. Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin. Thromb Res 89 (1998) 41-50
22. Hoppensteadt D.A., Wahi R., Adiguzel C., Iqbal O., Ramacciotti E., Bick R.L., et al. Contaminant in the recalled unfractionated heparin preparations: where is the problem?. Clin Appl Thromb Hemost 14 (2008) 261-266
23. Chen J., Avci F.Y., Muñoz E.M., McDowell L.M., Chen M., Pedersen L.C., et al. Enzymatic redesigning of biological active heparan sulfate. J Biol Chem 280 (2005) 42817-42825
24. Linhardt R.J., Al-Hakim A., Liu J.A., Hoppensteadt D., Mascellani G., Bianchini P., et al. Structural features of dermatan sulfates and their relationship to anticoagulant and antithrombotic activities. Biochem Pharmacol 42 (1991) 1609-1619
25. Samuel M., Pixley R.A., Villanueva M.A., Colman R.W., and Villanueva G.B. Human factor XII (Hageman factor) autoactivation by dextran sulfate. J Biol Chem 267 (1992) 19691-19697
26. Asakai R., Davie E.W., and Chung D.W. Organization of the gene for human factor XI. Biochemistry 26 (1987) 7221-7228
27. Gozzo A.J., Nunes V.A., Cruz-Sulva I., Carmona A., Nader H.B., Falijoni-Alario A., et al. Heparin modulation of human plasma kallikrein on different substrates and inhibitors. Biol Chem 387 (2006) 1129-1138
28. Discipio R.G. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 45 (1982) 587-595